Cancers, Vol. 16, Pages 1538: From Diabetes to Oncology: Glucagon-like Peptide-1 (GLP-1) Receptor Agonist & rsquo;s Dual Role in Prostate Cancer
Cancers, Vol. 16, Pages 1538: From Diabetes to Oncology: Glucagon-like Peptide-1 (GLP-1) Receptor Agonist’s Dual Role in Prostate Cancer
Cancers doi: 10.3390/cancers16081538
Authors:
Abdulrahman Alhajahjeh
Raad Al-Faouri
Hisham F. Bahmad
Taima’ Bader
Ryan W. Dobbs
Ahmed A. Abdulelah
Wassim Abou-Kheir
Elai Davicioni
David I. Lee
Mohammed Shahait
Glucagon-like peptide-1 (GLP-1), an incretin hormone renowned for its role in post-meal blood sugar regulation and glucose-dependent insulin secretion, has gained attention as a novel treatment for diabetes through GLP-1 receptor agonists (GLP-1...
Source: Cancers - April 18, 2024 Category: Cancer & Oncology Authors: Abdulrahman Alhajahjeh Raad Al-Faouri Hisham F. Bahmad Taima ’ Bader Ryan W. Dobbs Ahmed A. Abdulelah Wassim Abou-Kheir Elai Davicioni David I. Lee Mohammed Shahait Tags: Review Source Type: research
A Comprehensive Review on GLP-1 Signaling Pathways in the Management of Diabetes Mellitus - Focus on the Potential Role of GLP-1 Receptors Agonists and Selenium Among Various Organ Systems
Curr Diabetes Rev. 2024 Apr 16. doi: 10.2174/0115733998287178240403055901. Online ahead of print.ABSTRACTDiabetes Mellitus develops when the body becomes unable to fuel its cells with glucose, which results in the accumulation of sugar excess in the bloodstream. Because it has diverse pathophysiological impacts on the body, diabetes mellitus represents a significant issue of concern in an attempt to find suitable treatment modalities and medications for afflicted diabetic patients. Glucagon-like peptide 1 (GLP-1) plays a pivotal role in the incretin effect, emerging as a prospective treatment for diabetes mellitus and a pr...
Source: Current Diabetes Reviews - April 17, 2024 Category: Endocrinology Authors: Ghinwa Barakat Ghaith Assi Hussein Khalil Sami El Khatib Source Type: research
Targeting the incretin system in obesity and type 2 diabetes mellitus
This article reviews advances in incretin-based pharmacotherapy, including the latest glucagon-like peptide 1 (GLP1) receptor agonists (GLP1RAs), ‘GLP1 plus’ agents, which combine the benefits of these agonists with the activity of additional hormones, and oral GLP1RAs, which promise to extend the benefits of GLP1 therapy. (Source: Nature Reviews Endocrinology)
Source: Nature Reviews Endocrinology - April 17, 2024 Category: Endocrinology Authors: Saleem Ansari Bernard Khoo Tricia Tan Source Type: research
Patients with autoimmune liver disease have glucose disturbances that mechanistically differ from steatotic liver disease
Am J Physiol Gastrointest Liver Physiol. 2024 Apr 16. doi: 10.1152/ajpgi.00047.2024. Online ahead of print.ABSTRACTAutoimmune liver diseases are associated with an increased risk of diabetes, yet the underlying mechanisms remain unknown. In this cross-sectional study, we investigated the glucose-regulatory disturbances in patients with autoimmune hepatitis (AIH, n=19), primary biliary cholangitis (PBC, n=15), and primary sclerosing cholangitis (PSC, n=6). Healthy individuals (n=24) and patients with metabolic dysfunction-associated steatotic liver disease (MASLD, n=18) were included as controls. Blood samples were collecte...
Source: Am J Physiol Gastroi... - April 16, 2024 Category: Gastroenterology Authors: Anne-Sofie H Jensen Henriette Ytting Mikkel P Werge Elias B Rashu Liv E Hetland Mira Thing Puria Nabilou Johan Burisch Kirstine N Bojsen-M øller Anders E Junker Lise Hobolth Christian Mortensen Flemming Tofteng Flemming Bendtsen S øren Møller Mogens Vy Source Type: research
Patients with autoimmune liver disease have glucose disturbances that mechanistically differ from steatotic liver disease
Am J Physiol Gastrointest Liver Physiol. 2024 Apr 16. doi: 10.1152/ajpgi.00047.2024. Online ahead of print.ABSTRACTAutoimmune liver diseases are associated with an increased risk of diabetes, yet the underlying mechanisms remain unknown. In this cross-sectional study, we investigated the glucose-regulatory disturbances in patients with autoimmune hepatitis (AIH, n=19), primary biliary cholangitis (PBC, n=15), and primary sclerosing cholangitis (PSC, n=6). Healthy individuals (n=24) and patients with metabolic dysfunction-associated steatotic liver disease (MASLD, n=18) were included as controls. Blood samples were collecte...
Source: American Journal of Physiology. Gastrointestinal and Liver Physiology - April 16, 2024 Category: Physiology Authors: Anne-Sofie H Jensen Henriette Ytting Mikkel P Werge Elias B Rashu Liv E Hetland Mira Thing Puria Nabilou Johan Burisch Kirstine N Bojsen-M øller Anders E Junker Lise Hobolth Christian Mortensen Flemming Tofteng Flemming Bendtsen S øren Møller Mogens Vy Source Type: research
Patients with autoimmune liver disease have glucose disturbances that mechanistically differ from steatotic liver disease
Am J Physiol Gastrointest Liver Physiol. 2024 Apr 16. doi: 10.1152/ajpgi.00047.2024. Online ahead of print.ABSTRACTAutoimmune liver diseases are associated with an increased risk of diabetes, yet the underlying mechanisms remain unknown. In this cross-sectional study, we investigated the glucose-regulatory disturbances in patients with autoimmune hepatitis (AIH, n=19), primary biliary cholangitis (PBC, n=15), and primary sclerosing cholangitis (PSC, n=6). Healthy individuals (n=24) and patients with metabolic dysfunction-associated steatotic liver disease (MASLD, n=18) were included as controls. Blood samples were collecte...
Source: Am J Physiol Gastroi... - April 16, 2024 Category: Gastroenterology Authors: Anne-Sofie H Jensen Henriette Ytting Mikkel P Werge Elias B Rashu Liv E Hetland Mira Thing Puria Nabilou Johan Burisch Kirstine N Bojsen-M øller Anders E Junker Lise Hobolth Christian Mortensen Flemming Tofteng Flemming Bendtsen S øren Møller Mogens Vy Source Type: research
Incretin-based investigational therapies for the treatment of MASLD/MASH
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is the most common form of chronic liver disease. It exists as either simple steatosis or its more progressive form, metabolic dysfunction-associated steatohepatitis (MASH), formerly, non-alcoholic steatohepatitis (NASH). The global prevalence of MASLD is estimated to be 32% among adults and is projected to continue to rise with increasing rates of obesity, type 2 diabetes, and metabolic syndrome. (Source: Diabetes Research and Clinical Practice)
Source: Diabetes Research and Clinical Practice - April 16, 2024 Category: Endocrinology Authors: Bram Brouwers, Girish Rao, Yuanyuan Tang, Ángel Rodríguez, Leonard C Glass, Mark L Hartman Source Type: research
Reduced incretin effect precedes diabetes development following duodenopancreatectomy in individuals without diabetes
(Source: Journal of Clinical Investigation)
Source: Journal of Clinical Investigation - April 15, 2024 Category: Biomedical Science Authors: Gianfranco Di Giuseppe, Laura Soldovieri, Gea Ciccarelli, Pietro Manuel Ferraro, Giuseppe Quero, Francesca Cinti, Umberto Capece, Simona Moffa, Enrico Celestino Nista, Antonio Gasbarrini, Andrea Mari, Sergio Alfieri, Vincenzo Tondolo, Alfredo Pontecorvi, Source Type: research
Obesity - Standards, trends and advances
Adv Med Sci. 2024 Apr 9:S1896-1126(24)00022-1. doi: 10.1016/j.advms.2024.04.001. Online ahead of print.ABSTRACTObesity continues to be a significant global health concern, giving rise to various complications. This review article explores the current standards and emerging innovations in diagnosing and treating obesity, including recent disease name change, staging system or therapeutic goals. This narrative review has been based on recent scientific articles from PubMed database, limiting the scope of topics to current standards and upcoming developments and breakthroughs in the diagnosis and treatment of obesity. The edu...
Source: Advances in Medical Sciences - April 11, 2024 Category: Biomedical Science Authors: Jakub Go łacki Beata Matyjaszek-Matuszek Source Type: research
Obesity - Standards, trends and advances
Adv Med Sci. 2024 Apr 9;69(1):208-215. doi: 10.1016/j.advms.2024.04.001. Online ahead of print.ABSTRACTObesity continues to be a significant global health concern, giving rise to various complications. This review article explores the current standards and emerging innovations in diagnosing and treating obesity, including recent disease name change, staging system or therapeutic goals. This narrative review has been based on recent scientific articles from PubMed database, limiting the scope of topics to current standards and upcoming developments and breakthroughs in the diagnosis and treatment of obesity. The educational...
Source: Advances in Medical Sciences - April 11, 2024 Category: Biomedical Science Authors: Jakub Go łacki Beata Matyjaszek-Matuszek Source Type: research
Obesity - Standards, trends and advances
Adv Med Sci. 2024 Apr 9;69(1):208-215. doi: 10.1016/j.advms.2024.04.001. Online ahead of print.ABSTRACTObesity continues to be a significant global health concern, giving rise to various complications. This review article explores the current standards and emerging innovations in diagnosing and treating obesity, including recent disease name change, staging system or therapeutic goals. This narrative review has been based on recent scientific articles from PubMed database, limiting the scope of topics to current standards and upcoming developments and breakthroughs in the diagnosis and treatment of obesity. The educational...
Source: Advances in Medical Sciences - April 11, 2024 Category: Biomedical Science Authors: Jakub Go łacki Beata Matyjaszek-Matuszek Source Type: research
Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes
AbstractThe discovery of long-acting incretin receptor agonists represents a major stride forward in tackling the dual epidemic of obesity and diabetes. Here we outline the evolution of incretin-based pharmacotherapy, from exendin-4 to the discovery of the multi-incretin hormone receptor agonists that look set to be our next step toward curing diabetes and obesity. We discuss the multiagonists currently in clinical trials and the improvement in efficacy each new generation of these drugs bring. The success of these agents in preclinical models and clinical trials suggests a promising future for multiagonists in the treatme...
Source: Diabetes Therapy - April 4, 2024 Category: Endocrinology Source Type: research
DPP-4 inhibitors sitagliptin and PF-00734,200 mitigate dopaminergic neurodegeneration, neuroinflammation and behavioral impairment in the rat 6-OHDA model of Parkinson ’s disease
In conclusion, these studies support further evaluation of the repurposing of clinically approved gliptins as a treatment strategy for PD. (Source: AGE)
Source: AGE - April 2, 2024 Category: Geriatrics Source Type: research
Multifunctional host-defense peptides isolated from skin secretions of the banana tree dwelling frog Boana platanera (Hylidae; Hylinae)
Biochimie. 2024 Mar 30:S0300-9084(24)00070-1. doi: 10.1016/j.biochi.2024.03.012. Online ahead of print.ABSTRACTFive host-defense peptides (figainin 2PL, hylin PL, raniseptin PL, plasticin PL, and peptide YL) were isolated from norepinephrine-stimulated skin secretions of the banana tree dwelling frog Boana platanera (Hylidae; Hylinae) collected in Trinidad. Raniseptin PL (GVFDTVKKIGKAVGKFALGVAKNYLNS.NH2) and figainin 2PL (FLGTVLKLGKAIAKTVVPMLTNAMQP KQ.NH2) showed potent and rapid bactericidal activity against a range of clinically relevant Gram-positive and Gram-negative ESKAPE + pathogens and Clostridioides difficile. The...
Source: Biochimie - April 1, 2024 Category: Biochemistry Authors: J Michael Conlon Ananyaa Sridhar Dawood Khan Taylor S Cunning Jack J Delaney Megan G Taggart Nigel G Ternan J érôme Leprince Laurent Coquet Thierry Jouenne Samir Attoub Milena Mechkarska Source Type: research
